Physician profile
Shelly Dutt
NPI 1487065215
$607.62
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $516 · 2021: $91.80.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $155.86 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $88.86 | 2020 | |
| Amgen INC. | $64.17 | 2020 | |
| Abbvie INC. | $63.09 | 2020 | |
| Glaxosmithkline, LLC. | $51.61 | 2020 | |
| Pfizer INC. | $42.59 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.48 | 2020 | |
| Novo Nordisk INC | $28.56 | 2020 | |
| Merck Sharp & Dohme LLC | $22.84 | 2020 | |
| Covidien LP | $21.03 | 2020 | |
| Therapeuticsmd, INC. | $15.16 | 2020 | |
| Mylan Specialty L.P. | $14.37 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shelly Dutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.